Sentence examples for a difference in relapse from inspiring English sources

A lack of a difference in relapse rate may suggest that the pro-inflammatory properties of increased prolactin during breast feeding may not be clinically significant.

A difference in relapse rate between the lactobacilli group and the placebo group of at least 20% was considered clinically relevant.

Our RFS analyses were negative, although few events had occurred, limiting the power of this analysis (post hoc analysis revealed 10% power to detect a difference in relapse between those with vitD levels ≥ and <30 ng/mL).

Specifically, although there was a difference in relapse rates at EOT between carriers and non-carriers for individuals who received bupropion, there was a substantial increase in relapse rates for those individuals carrying the minor allele after they went off treatment.

The analysis that assessed the outcomes of patients in groups I and II did not reveal a mortality difference (Group I: 4/22; 18% vs. Group II: 50/419; 12%, p = 0.33) or a differences in relapse of infection with the same bacteria (Group I: 3/22; 14% vs. Group II: 27/419, 6.4%, p = 0.182).

When the yearly relapse hazard for OLAI is set to equal that for RLAI, implying absence of any difference in relapse hazard between OLAI and RLAI, the ICERs for OLAI are dominant for both QALY and for relapse avoided ratios.

To assess any difference in relapse rates between the experimental group and the control groups (TAU group and matched historical group) at 3 month after detoxification Pearson Chi-squared test will be used for the dichotomous abstinence rates.

Univariate analysis of EDD expression identified a significant association between EDD expression and disease recurrence (HR 1.75, P=0.011; Table 3) with a difference in median relapse time of 15.1 vs 17.3 months for patients with high and low EDD expression, respectively.

There is no obvious explanation for this discrepancy; but the study of Chang et al. included the largest sample of patients with therapy-related disease, and may, therefore, have had more power to detect a difference in the relapse rate specific to this population.

Froud et al (2000) did not find a difference in systemic relapses of RT administered up to 12 weeks after surgery, but again 34.5% patients received adjuvant hormonal therapy.

However, the Kaplan Meier analysis in our study did not show a significant difference in relapse rate according to treatment duration (<24 mo vs. >24 mo) in HBeAg-positive CHB, and consolidation of more than 12 months did not decrease relapse rates compared with a shorter consolidation period (data not shown).